Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab
详细信息 查看全文
- 作者：Philipp Kickingereder ; Benedikt Wiestler ; Markus Graf…
- 关键词：Glioblastoma ; Dynamic contrast ; enhanced MRI ; Bevacizumab ; Volume transfer constant (Ktrans)
- 刊名：Journal of Neuro-Oncology
- 出版年：2015
- 出版时间：January 2015
- 年：2015
- 卷：121
- 期：2
- 页码：373-380
- 全文大小：2,047 KB
- 参考文献：1. Wong ET, Brem S (2008) Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Natl Compr Cancer Netw 6:515-22
2. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8:610-22. doi:10.1038/nrn2175/nrn2175 CrossRef
3. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963-972 CrossRef
4. Leu K, Pope WB, Cloughesy TF, Lai A, Nghiemphu PL, Chen W, Liau LM, Ellingson BM (2013) Imaging biomarkers for antiangiogenic therapy in malignant gliomas. CNS Oncol 2:33-7. doi:10.2217/cns.12.29 CrossRef
5. O’Connor JP, Jayson GC (2012) Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors? Clin Cancer Res 18:6588-598. doi:10.1158/1078-0432.CCR-12-1501 CrossRef
6. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ (2013) Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31:1219-230. doi:10.1200/JCO.2012.46.2762 CrossRef
7. Tofts PS (2010) T1-weighted DCE imaging concepts: modelling, acquisition and analysis. MAGNETOM Flash 3:30-9
8. Cha S (2006) Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 27:475-87
9. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-5. doi:10.1016/j.ccr.2006.11.021 CrossRef
10. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK (2009) A “vascular normalization index-as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69:5296-300. doi:10.1158/0008-5472.CAN-09-0814 CrossRef
11. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223-32 CrossRef
12. Mouridsen K, Christensen S, Gyldensted L, Ostergaard L (2006) Automatic selection of arterial input function using cluster analysis. Magn Reson Med 55:524-31. doi:10.1002/mrm.20759 CrossRef
13. Murase K (2004) Efficient method for calculating kinetic parameters using T1-weighted dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Med 51:858-62. doi:10.1002/mrm.20022 CrossRef
14. Galban CJ, Chenevert TL, Meyer CR, Tsien C, Lawrence TS, Hamstra DA, Junck L, Sundgren PC, Johnson TD, Ross DJ, Rehemtulla A, Ross BD (2009) The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 15:572-76. doi:10.1038/nm.1919
文摘
Bevacizumab, an antibody to vascular endothelial growth factor, is commonly used in the setting of recurrent glioblastoma (rGB). The aim of the present study was to evaluate whether dynamic-contrast-enhanced MRI (DCE-MRI) derived microvascular permeability is related to bevacizumab treatment outcome in rGB. Twenty-two patients with rGB underwent DCE-MRI at a median of 2.6?weeks prior initializing bevacizumab therapy. Follow-up MRI-scans (DCE-MRI available for 19/22 patients) were obtained after a median of 9.9?weeks. The volume transfer constant (Ktrans)—an estimate related to microvascular permeability—at baseline and voxel-wise-reduction (VWR) in Ktrans at first follow-up were measured from the entire contrast-enhancing tumor (CET) and correlated with progression-free and overall survival (PFS, OS) using uni- and multivariate cox-regression (significance-level p?trans ranged from 0.050 to 0.205?min? (median, 0.109?min?). The VWR in Ktrans ranged from 19.9 to 97.2?% (median, 89.4?%). Patients with lower baseline Ktrans and higher VWR in Ktrans showed significantly longer PFS and OS. Given the strong correlation of VWR in Ktrans and CET-volume changes (Spearman’s ρ?=??.73, p?trans nor CET-volume changes retained independent significance for PFS or OS. Pre-treatment Ktrans stratifies PFS and OS in patients with bevacizumab-treated rGB. Although early pharmacodynamics changes in Ktrans were not assessed, the VWR in Ktrans at first follow-up had no additional benefit over assessment of CET-volume changes. Further prospective trials are needed to confirm these findings and to elucidate the potential role of pre-treatment Ktrans as a predictive and/or prognostic biomarker.